RAC-GS Q&As

Regulatory Affairs Certification (RAC) Global Scope

Pass RAPS RAC-GS Exam with 100% Guarantee

Free Download Real Questions & Answers **PDF** and **VCE** file from:

https://www.pass4itsure.com/rac-gs.html

100% Passing Guarantee
100% Money Back Assurance

Following Questions and Answers are all new published by RAPS Official Exam Center

- **Instant Download** After Purchase
- **100% Money Back** Guarantee
- **365 Days** Free Update
- **800,000+** Satisfied Customers

QUESTION 1

The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon.

Which is the most appropriate action for the regulatory affairs professional to take FIRST?

A. Transfer the notice of the upcoming international monograph change to QA for further processing.

B. Prepare the international monograph change submission first and then prepare the local change when required.

C. Confirm that the international monograph change is not related to local pharmacopeia.

D. Analyze the impact of the international monograph change on the local pharmacopeia.

Correct Answer: AB

QUESTION 2

Company X is planning to acquire the rights for a product marketed by Company Y. As part of due diligence, what is the MOST important information the Company X regulatory affairs professional should ask senior management to request from Company Y?

A. Intellectual properly

B. Clinical trial data

C. Safety issues

D. Marketing materials

Correct Answer: C

QUESTION 3

Which term does NOT describe the same concept as the others?

A. Biosimilars

B. Follow-on protein products

C. Monoclonal antibody

D. Subsequent entry biologics

Correct Answer: C

QUESTION 4

The regulatory authority in Country X issued a request for a mandatory product recall in Country X due to serious injuries to patients. This product also is distributed in Country Y.

What should the regulatory affairs professional of the product\\'s manufacturer FIRST do in Country Y?

A. Draft a formal letter to customers in Country Y about this recall.

B. Initiate a mandatory recall of the product in Country Y.

C. Review alt distribution records and complaints reported in Country Y.

D. Prepare the legal team in Country Y for possible litigations.

Correct Answer: C

QUESTION 5

At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?

A. Quality improvement

B. Quality assurance

C. Clinical affairs

D. Regulatory agency

Correct Answer: B

QUESTION 6

Company X and Company Y both have products for the treatment of rare genetic diseases. Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.

What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?

A. Enter into an agreement with Company Y to perform due diligence.

B. Recruit a professional to gather confidential intelligence on Company Y.

C. Request the needed information from the Board of Directors of Company Y.

D. Perform a thorough library search to gather detailed information on Company Y.

Correct Answer: A

QUESTION 7

A company is developing a new line of products in an area that is new to the company. What is the BEST approach?

A. Ask the trade association representative to provide an overview of the new product area to the marketing team.

B. Obtain competitor research and provide the information to the management team.

C. Obtain regulatory documents and history and provide the information to RandD.

D. Summarize regulatory documents and history and provide the information to the management team.

Correct Answer: D

QUESTION 8

GHTF recommends that the medical device manufacturer define the scope of the clinical evaluation based on which of the following?

A. Instructions for use

B. Risk analysis

C. Product literature

D. Essential principles

Correct Answer: BD

QUESTION 9

A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.

During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that

the product will be approved based on a recent withdrawal of a similar product in another country.

What is the BEST response?

A. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application.

B. Consult with the legal department to discuss the best course of action.

C. Review the regulatory guidelines to determine how to proceed.

D. Request a meeting with the regulatory authority to discuss the application.

Correct Answer: D

QUESTION 10

According to the ICH guideline on GMP for API,to which of the following is the MOST stringent requirement applied?

A. Physical processing and packaging

B. Isolation and purification

C. Production of Intermediate(s)

D. Introduction of the API starting material

Correct Answer: A

QUESTION 11

In a distribution contract for high-risk medical devices, which of the following regulatory requirements is the MOST important for the distributor?

A. Local reimbursement requirements

B. Service operation procedures

C. Training program for sales people

D. Written procedure for product traceability

Correct Answer: C

QUESTION 12

Which of the following BEST describes the content of the "Physical, Chemical, and Pharmaceutical Properties and Formulation" section of an IB?

A. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation

B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use

C. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product

D. A brief summary of relevant physical, chemical, and pharmaceutical properties: instructions for storage and handling of the dosage form: and a description of the formulation

Correct Answer: D

QUESTION 13

Under which of the following circumstances would a regulatory authority require a more detailed premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data than would normally apply to an IVD device of that risk class?

A. The device is an updated version of a compliant device from the same manufacturer and contains no substantive change.

B. Internationally recognized standards are available to cover the main aspects of the device and have been used by the manufacturer.

C. The manufacturer\\'s experience level with the type of IVD medical device is limited.

D. The device incorporates well-established technology that is already present in the market.

Correct Answer: C

QUESTION 14

Which of the following claims would classify an apple as a drug?

A. "It will make you look younger."

B. "It will satisfy hunger."

C. "It will whiten teeth."

D. "It will prevent colds."

Correct Answer: D

QUESTION 15

One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority\\'s request?

A. "Given the advisory committee\\'s unanimous decision, we know that the product will not be approved, and additional data will not make any difference."

B. "We have no additional informationto provide at this time, but wecan perform an additional analysis for a specific safety concern, if necessary."

C. "We disagree with the advisory committee\\'s decision because the committee neglected the thorough safety analysis that we provided."

D. "We have no additional information to provide at this time because we have already provided everything needed to support our product\\'s approval."

Correct Answer: B